Olanzapine

Evidence Level: L5

Predicted Indications: 2

Olanzapine

Pharmacist Assessment Report

Olanzapine: From Bipolar Disorder and Schizophrenia to Benign Paroxysmal Torticollis of Infancy

One-Sentence Summary

Olanzapine is an atypical antipsychotic originally used for schizophrenia, bipolar disorder, depression and anxiety disorders. The TxGNN model predicts it may be effective for benign paroxysmal torticollis of infancy, but no clinical trials and no publications currently support this specific prediction. The next two predictions, agoraphobia and dysthymic disorder, have limited indirect literature (6 and 5 publications respectively) and no registered trials.

Quick Overview

Item	Content
Original Indication	Bipolar disorder, manic bipolar affective disorder, unipolar depression, endogenous depression, major depressive disorder, anxiety disorder, schizophrenia (the Canadian licence records contain no indication text)
Predicted New Indication	Benign paroxysmal torticollis of infancy
TxGNN Prediction Score	0.9954
Evidence Level	L5
Canada Market Status	Marketed (marketed DINs on record: at least 20)
Number of DINs	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, olanzapine is an antipsychotic whose efficacy in schizophrenia and bipolar disorder is established. Its pharmacology is generally attributed to dopamine and serotonin receptor antagonism, but this could not be verified from the data compiled for this report.

Benign paroxysmal torticollis of infancy is a rare, self-limiting pediatric episodic disorder. It is related to the migraine spectrum and to CACNA1A channelopathies. No established mechanistic link to olanzapine’s receptor pharmacology was identified. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related neurological or movement phenotypes, not biological evidence or a true pharmacological rationale.

Because the condition is benign and resolves on its own in infants, the risk-benefit balance for an antipsychotic with metabolic and sedative adverse effects is unfavourable.

Other Predicted Indications Reviewed

Rank	Predicted Indication	TxGNN Score	Evidence Level	Assessment
2	Agoraphobia	0.9947	L5	Research question. Plausible link through panic disorder and anxiety, supported only by small uncontrolled studies.

Clinical Trial Evidence

Currently no related clinical trials registered for benign paroxysmal torticollis of infancy. No registered trials were found for agoraphobia or dysthymic disorder either.

Literature Evidence

No related literature is currently available for benign paroxysmal torticollis of infancy.

For reference, the literature found for the two next-ranked predictions is shown below.

Agoraphobia (rank 2)

PMID	Year	Type	Journal	Key Findings
16415705	2006	Open-label trial	J Clin Psychopharmacol	12-week trial of olanzapine 5 mg/day added to an SSRI in 31 patients with SSRI-resistant panic disorder, with or without agoraphobia
26635099	2016	Systematic review	Expert Opin Pharmacother	Treatment-resistant panic disorder: about one-third of patients remain symptomatic after treatment
40946318	2026	Systematic review	Psychother Psychosom	Pharmacological, psychotherapeutic and neurostimulatory options for treatment-resistant anxiety disorders
25012437	2014	Cohort	J Affect Disord	Impact of comorbid anxiety disorders, including agoraphobia, on 24-month outcomes in bipolar I disorder
10739446	2000	Letter	Am J Psychiatry	Olanzapine and panic attacks
15470803	2004	Case report	Pharmacopsychiatry	Remission of panic disorder after olanzapine plus paroxetine

PMID	Year	Type	Journal	Key Findings
21154393	2010	Systematic review	Cochrane Database Syst Rev	Second-generation antipsychotics as add-on treatment for major depressive disorder and dysthymia
10578457	1999	Open-label study	Biol Psychiatry	Olanzapine safety and efficacy in borderline personality disorder with comorbid dysthymia
22938165	2012	Review	Bipolar Disord	Evidence-based options for treatment-resistant bipolar disorder
11920152	2002	Review	Mol Psychiatry	Substituted benzamides in dysthymia (a different drug class)
34727399	2021	Systematic review	Hum Psychopharmacol	Amisulpride for depressive symptoms (a different drug)

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02229285	ZYPREXA	Not specified	Not specified
02243086	ZYPREXA ZYDIS	Not specified	Not specified
02303175	PMS-OLANZAPINE	Not specified	Not specified
02276739	TEVA-OLANZAPINE	Not specified	Not specified
02281791	APO-OLANZAPINE	Not specified	Not specified

There are 20 valid single-ingredient licences in total, including brand, generic and orally disintegrating tablet (ODT) products.

Safety Considerations

Disease-level contraindications (knowledge graph): These come from drug-disease relationships in the knowledge graph, not from package insert text. They include:
- Metabolic conditions: diabetes mellitus, diabetic ketoacidosis, hyperglycaemia, hyperlipidaemia, hypertriglyceridaemia, obesity
- Liver conditions: liver failure, liver disease, cirrhosis, gallbladder disease
- Blood conditions: neutropenia, agranulocytosis, blood coagulation disease
- Cardiovascular and cerebrovascular conditions: orthostatic hypotension, hypotensive disorder, myocardial infarction, stroke, cerebral infarction, cerebrovascular disorder, coronary thrombosis
- Other: epilepsy, benign prostatic hyperplasia, female breast carcinoma, multiple system atrophy, postural orthostatic tachycardia syndrome
Drug Interactions: 100 interactions were recorded. Major-level examples include bupropion, morphine and potassium citrate. Moderate-level examples include metformin, acarbose, alogliptin, canagliflozin, dapagliflozin, chlorpropamide, famotidine, epinephrine, clarithromycin, and several anticholinergic agents (atropine, hyoscyamine, glycopyrronium).
Rationale-level concerns: Metabolic risk (weight gain, metabolic syndrome) and sedation are particular concerns for long-term use in a benign or chronic lower-severity condition.

The package insert warnings and contraindications from Health Canada were not available, so please refer to the package insert for the full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is very high (0.9954), but there are no trials or publications for benign paroxysmal torticollis of infancy, and no plausible mechanistic link. The condition is self-limiting in infants, and olanzapine’s metabolic and sedative risks make the risk-benefit balance unfavourable. Agoraphobia and dysthymic disorder are better-supported research questions (L3), but both rely on small, uncontrolled or indirect evidence.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications, which currently block safety screening
Mechanism of action data for olanzapine
For agoraphobia: a controlled trial of olanzapine augmentation in panic disorder with agoraphobia, compared against first-line SSRIs and CBT
For dysthymic disorder: a dysthymia-specific randomised trial of olanzapine, with long-term metabolic monitoring
For the top-ranked prediction: expert review to determine whether any biological rationale exists, given the CACNA1A channelopathy and migraine-spectrum background
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.